Cocrystal Pharma, Inc.
17.80%
2,462,012
1412486
19188J409
Oct 27, 2025
Oct 30, 2025, 04:42 PM
Reporting Persons (2)
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Phillip Frost, M.D. | Individual | 17.80% | 2,462,012 | 1,694,794 | 0 |
| Frost Gamma Investments Trust | Other | 17.40% | 2,398,977 | 1,679,551 | 0 |
Disclosure Items (7)
Common Stock, par value $0.001 per share
Cocrystal Pharma, Inc.
19805 N. CREEK PARKWAY, BOTHELL, WA, 98011
This Amendment is filed on behalf of Phillip Frost, M.D. and FGIT (together, the "Reporting Persons").
The principal business address of the Reporting Persons is 4400 Biscayne Boulevard, Miami, Florida 33137.
During the last five years, none of the Reporting Persons (or their directors, officers, or controllers, if applicable) have been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding were or are subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violations with respect to such laws.
Dr. Frost is a citizen of the United States of America. FGIT was organized in the State of Florida.
On October 28, 2025, the Reporting Person purchased units at $1.39 per unit with each unit consisting of one share of common stock and a warrant to purchase two shares of common stock, acquiring 359,713 shares of the Issuer's common stock and 719,426 warrants to purchase shares of the Issuer's common stock.
The beneficial ownership percentages disclosed below are based on 13,039,350 shares of common stock outstanding as of September 18, 2025, 47,792 shares of common stock issuable upon exercise of options and 719,426 shares of common stock issuable upon exercise of warrants, both within 60 days. Dr. Frost is the beneficial owner of 2,462,012 shares of common stock representing 17.8% of the shares outstanding of the Issuer, including (i) 1,679,551 shares of common stock held by FGIT, (ii) 15,243 shares of the Issuer's common stock held by the Reporting Person, (iii) 47,792 shares of common stock issuable upon exercise of vested options and (iv) 719,426 shares of common stock issuable upon exercise of warrants. Dr. Frost is the trustee of FGIT. Frost Gamma Limited Partnership is the sole and exclusive beneficiary of FGIT. Dr. Frost is one of two limited partners of Frost Gamma Limited Partnership. Dr. Frost is the sole shareholder of Frost-Nevada Corporation, which is the sole shareholder of Frost Gamma, Inc., the general partner of Frost Gamma Limited Partnership. As a result of the foregoing, Dr. Frost may be deemed the beneficial owner of the shares of common stock held by FGIT. Dr. Frost disclaims beneficial ownership of the securities held by FGIT except to the extent of any pecuniary interest therein. Dr. Frost has sole dispositive power with respect to 47,792 shares of common stock issuable upon exercise of vested options.
The Reporting Persons have voting and dispositive power over the Issuer's securities as described above in Item 5(a).
Except as described in this Schedule 13D under Item 3 above, the Reporting Persons did not engage in any transactions in shares of the Company's common stock during the past 60 days.
Not Applicable.
Not Applicable.
Not applicable.
None.